Educating physicians about ventilation-perfusion scanning as an alternative to CT for the diagnosis of pulmonary embolisms led to a 23 percent decrease in patient exposure, according to a study ...

The US Food and Drug Administration (FDA) has granted 510(k) clearance to 4DMedical’s non-contrast, computed tomography (CT)-based ventilation-perfusion imaging technology, CT:VQ, for respiratory ...

DMedical Limited has announced a significant expansion of its distribution agreement with Philips, which will now include the CT:VQ™ technology in its North American product catalogue. This deal, ...

4DMedical Limited has unveiled its innovative CT:VQ technology at RSNA 2024, offering a revolutionary alternative to traditional Nuclear VQ scans. This new imaging solution promises faster, safer, and ...

US FDA assent for 4D Medical’s CT VQ ventilation perfusion device described by the company as a “transformational milestone”. It all started in August when the lung scanning innovator inked a deal ...

Hi, everyone. Thank you so much for joining us today and for your interest in 4DMedical and today's investor presentation. Of course, the key focus of today's presentation is going to be CT:VQ post ...

At the time of writing, the ASX tech stock is up 18% to $1.96. Investors have been scrambling to buy the respiratory imaging ...

Educating physicians about ventilation-perfusion scanning (VQ) as an alternative to CT for the diagnosis of pulmonary embolisms led to a 23% decrease in patient exposure, according to a study ...

It all started in August when the lung scanning innovator inked a deal with the giant ASX-listed Pro Medicus, involving a $10 million loan and the hint of other liaisons to come. On September 1, 4D ...